CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01, Zacks reports. CollPlant Biotechnologies had a negative return on equity of 161.69% and a negative net margin of 353.70%.The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.46 million.
CollPlant Biotechnologies Stock Performance
Shares of CLGN stock opened at $0.40 on Friday. The company has a market cap of $5.79 million, a P/E ratio of -0.28 and a beta of 1.47. The stock has a 50 day simple moving average of $0.44 and a two-hundred day simple moving average of $1.06. CollPlant Biotechnologies has a fifty-two week low of $0.27 and a fifty-two week high of $4.98.
Analyst Ratings Changes
A number of analysts have recently commented on CLGN shares. D. Boral Capital lowered CollPlant Biotechnologies from a “buy” rating to a “hold” rating in a research note on Friday, February 6th. Weiss Ratings lowered CollPlant Biotechnologies from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $11.50.
CollPlant Biotechnologies Company Profile
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.
CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.
Further Reading
- Five stocks we like better than CollPlant Biotechnologies
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
